Artificial Emotion Generation Based on Personality, Mood, and Emotion for Life-Like Facial Expressions of Robots

International audienceWe can't overemphasize the importance of robot's emotional expressions as robots step into human's daily lives. So, the believable and socially acceptable emotional expressions of robots are essential. For such human-like emotional expression, we have proposed an emotion generation model considering personality, mood and history of robot's emotion. The personality module is based on the Big Five Model (OCEAN Model, Five Factor Model); the mood module has one dimension such as good or bad, and the emotion module uses the six basic emotions as defined by Ekman. Unlike most of the previous studies, the proposed emotion generation model was integrated with the Linear Dynamic Affect Expression Model (LDAEM), which is an emotional expression model that can make facial expressions similar to those of humans. So, both the emotional state and expression of robots can be changed dynamically

Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin

Huntington's disease (HD), a progressive neurodegenerative disease, is caused by an expanded CAG triplet repeat producing a mutant huntingtin protein (mHTT) with a polyglutamine-repeat expansion. Onset of symptoms in mutant huntingtin gene-carrying individuals remains unpredictable. We report that synthetic polyglutamine oligomers and cerebrospinal fluid (CSF) from BACHD transgenic rats and from human HD subjects can seed mutant huntingtin aggregation in a cell model and its cell lysate. Our studies demonstrate that seeding requires the mutant huntingtin template and may reflect an underlying prion-like protein propagation mechanism. Light and cryo-electron microscopy show that synthetic seeds nucleate and enhance mutant huntingtin aggregation. This seeding assay distinguishes HD subjects from healthy and non-HD dementia controls without overlap (blinded samples). Ultimately, this seeding property in HD patient CSF may form the basis of a molecular biomarker assay to monitor HD and evaluate therapies that target mHTT